238 related articles for article (PubMed ID: 31278259)
1. Untangling the evolutionary roots of lung cancer.
Devarakonda S; Govindan R
Nat Commun; 2019 Jul; 10(1):2979. PubMed ID: 31278259
[TBL] [Abstract][Full Text] [Related]
2. CDK1 serves as a potential prognostic biomarker and target for lung cancer.
Li M; He F; Zhang Z; Xiang Z; Hu D
J Int Med Res; 2020 Feb; 48(2):300060519897508. PubMed ID: 32020821
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic efficiency of seven autoantibodies in lung cancer.
Huang H; Luo W; Ni Y; Sun S; Wang C; Zhang L
Eur J Cancer Prev; 2020 Jul; 29(4):315-320. PubMed ID: 31764214
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC.
Tian Y; Zhai X; Yan W; Zhu H; Yu J
Cancer Med; 2021 Jan; 10(1):3-14. PubMed ID: 33230935
[TBL] [Abstract][Full Text] [Related]
5. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of NAP1L1 expression in patients with early lung adenocarcinoma.
Nagashio R; Kuchitsu Y; Igawa S; Kusuhara S; Naoki K; Satoh Y; Ichinoe M; Murakumo Y; Saegusa M; Sato Y
Biomed Res; 2020; 41(3):149-159. PubMed ID: 32522932
[TBL] [Abstract][Full Text] [Related]
7. Immune subgroup analysis for non-small cell lung cancer may be a good choice for evaluating therapeutic efficacy and prognosis.
Tian Y; Wang J; Wen Q; Su G; Sun Y
Aging (Albany NY); 2021 May; 13(9):12691-12709. PubMed ID: 33973529
[TBL] [Abstract][Full Text] [Related]
8. Identification of diagnostic DNA methylation biomarkers specific for early-stage lung adenocarcinoma.
Cai Q; Zhang P; He B; Zhao Z; Zhang Y; Peng X; Xie H; Wang X
Cancer Genet; 2020 Aug; 246-247():1-11. PubMed ID: 32805686
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of immune-related genes in the tumor microenvironment of lung adenocarcinoma and lung squamous cell carcinoma.
Qu Y; Cheng B; Shao N; Jia Y; Song Q; Tan B; Wang J
Aging (Albany NY); 2020 Mar; 12(6):4757-4777. PubMed ID: 32209727
[TBL] [Abstract][Full Text] [Related]
10. Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.
Kratz JR; Haro GJ; Cook NR; He J; Van Den Eeden SK; Woodard GA; Gubens MA; Jahan TM; Jones KD; Kim IJ; He B; Jablons DM; Mann MJ
J Thorac Oncol; 2019 Jul; 14(7):1223-1232. PubMed ID: 30959120
[TBL] [Abstract][Full Text] [Related]
11. T-cell exhaustion interrelates with immune cytolytic activity to shape the inflamed tumor microenvironment.
Cai MC; Zhao X; Cao M; Ma P; Chen M; Wu J; Jia C; He C; Fu Y; Tan L; Xue X; Yu Z; Zhuang G
J Pathol; 2020 Jun; 251(2):147-159. PubMed ID: 32222046
[TBL] [Abstract][Full Text] [Related]
12. Sputum long non-coding RNA biomarkers for diagnosis of lung cancer.
Gupta C; Su J; Zhan M; Stass SA; Jiang F
Cancer Biomark; 2019; 26(2):219-227. PubMed ID: 31450489
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of Bronchial Washing Fluid-Based Approach to Early-Stage Lung Cancer Diagnosis.
Ryu JS; Lim JH; Lee MK; Lee SJ; Kim HJ; Kim MJ; Park MH; Kim JS; Nam HS; Park N; Yong SJ
Oncologist; 2019 Jul; 24(7):e603-e606. PubMed ID: 31036768
[TBL] [Abstract][Full Text] [Related]
14. Integrating Imaging, Histologic, and Genetic Features to Predict Tumor Mutation Burden of Non-Small-Cell Lung Cancer.
Zhang N; Wu J; Yu J; Zhu H; Yang M; Li R
Clin Lung Cancer; 2020 May; 21(3):e151-e163. PubMed ID: 31734072
[TBL] [Abstract][Full Text] [Related]
15.
Goto D; Komeda K; Uwatoko N; Nakashima M; Koike M; Kawai K; Kodama Y; Miyazawa A; Tanaka I; Hase T; Morise M; Hasegawa Y; Kawabe T; Sato M
Cancer Invest; 2020 Apr; 38(4):240-249. PubMed ID: 32212938
[TBL] [Abstract][Full Text] [Related]
16. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
[TBL] [Abstract][Full Text] [Related]
17. Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas.
Sands JM; Nguyen T; Shivdasani P; Sacher AG; Cheng ML; Alden RS; Jänne PA; Kuo FC; Oxnard GR; Sholl LM
Lung Cancer; 2020 Feb; 140():35-41. PubMed ID: 31855703
[TBL] [Abstract][Full Text] [Related]
18. Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments.
Fukuda H; Arai K; Mizuno H; Nishito Y; Motoi N; Arai Y; Hiraoka N; Shibata T; Sonobe Y; Kayukawa Y; Hashimoto E; Takahashi M; Fujii E; Maruyama T; Kuwabara K; Nishizawa T; Mizoguchi Y; Yoshida Y; Watanabe SI; Yamashita M; Kitano S; Sakamoto H; Nagata Y; Mitsumori R; Ozaki K; Niida S; Kanai Y; Hirayama A; Soga T; Tsukada K; Yabuki N; Shimada M; Kitazawa T; Natori O; Sawada N; Kato A; Yoshida T; Yasuda K; Ochiai A; Tsunoda H; Aoki K
Cancer Sci; 2024 Jun; 115(6):1763-1777. PubMed ID: 38527308
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA dysregulational synergistic network: discovering microRNA dysregulatory modules across subtypes in non-small cell lung cancers.
Tran N; Abhyankar V; Nguyen K; Weidanz J; Gao J
BMC Bioinformatics; 2018 Dec; 19(Suppl 20):504. PubMed ID: 30577741
[TBL] [Abstract][Full Text] [Related]
20. Serum Protein Markers for the Early Detection of Lung Cancer: A Focus on Autoantibodies.
Broodman I; Lindemans J; van Sten J; Bischoff R; Luider T
J Proteome Res; 2017 Jan; 16(1):3-13. PubMed ID: 27769114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
